Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H14ClNO |
Molecular Weight | 211.688 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(CCNCC1)C2=CC=C(Cl)C=C2
InChI
InChIKey=LZAYOZUFUAMFLD-UHFFFAOYSA-N
InChI=1S/C11H14ClNO/c12-10-3-1-9(2-4-10)11(14)5-7-13-8-6-11/h1-4,13-14H,5-8H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1599504Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24827597 | http://www.hmdb.ca/metabolites/HMDB60902
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1599504
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24827597 | http://www.hmdb.ca/metabolites/HMDB60902
4-(4-Chlorophenyl)-4-piperidinol (CPPO) is one of haloperidol metabolite. Neurotoxicity studies in frogs, which have been used to detect N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) action, showed that CPPO did not mimic the neurotoxicity of MPTP but caused a delayed and persistent freezing action in Rana pipiens frogs. It is proposed that this action may contribute to some of the delayed side-effects associated with haloperidol therapy.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24827597 |
9090.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and pharmacological activity of 4-(4'-(chlorophenyl)-4-hydroxypiperidine) derivatives. | 2005 Jan |
|
Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage. | 2005 Jul-Aug |
|
Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. | 2005 Jun |
|
Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. | 2006 Dec |
|
Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection. | 2006 Feb |
|
Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid. | 2006 Oct |
|
Sensitive determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, in a rat biological sample by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. | 2006 Sep |
|
4-(4-Chloro-phen-yl)piperidin-4-ol. | 2010 Feb 6 |
|
4-(4-Chloro-phen-yl)-4-hy-droxy-piperidinium maleate maleic acid solvate. | 2010 Jul 14 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24827597
Cell membranes (D2L-FlpIn CHO, 3 μg) were incubated with varying concentrations of test compound 7 (4-(4-Chlorophenyl)-4-piperidinol) in binding buffer (20 mM HEPES, 100 mM NaCl, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 7.4) containing 0.05 nM of [3H]spiperone and 100 μM GppNHp to a final volume of 1 mL and were incubated at 37 °C for 3 h. Binding was terminated by fast-flow filtration over GF/B membranes using a Brandel harvester followed by three washes with ice-cold 0.9% NaCl. Bound radioactivity was measured in a Tri-Carb 2900TR liquid scintillation counter (PerkinElmer).
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
89568
Created by
admin on Sat Dec 16 04:41:34 GMT 2023 , Edited by admin on Sat Dec 16 04:41:34 GMT 2023
|
PRIMARY | |||
|
UND92FKS0W
Created by
admin on Sat Dec 16 04:41:34 GMT 2023 , Edited by admin on Sat Dec 16 04:41:34 GMT 2023
|
PRIMARY | |||
|
DTXSID7057733
Created by
admin on Sat Dec 16 04:41:34 GMT 2023 , Edited by admin on Sat Dec 16 04:41:34 GMT 2023
|
PRIMARY | |||
|
254-479-8
Created by
admin on Sat Dec 16 04:41:34 GMT 2023 , Edited by admin on Sat Dec 16 04:41:34 GMT 2023
|
PRIMARY | |||
|
38282
Created by
admin on Sat Dec 16 04:41:34 GMT 2023 , Edited by admin on Sat Dec 16 04:41:34 GMT 2023
|
PRIMARY | |||
|
39512-49-7
Created by
admin on Sat Dec 16 04:41:34 GMT 2023 , Edited by admin on Sat Dec 16 04:41:34 GMT 2023
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD